Summary
Amgen Inc. reported strong financial performance for the third quarter and first nine months of 2025, with total revenues increasing by 12% and 11% year-over-year, respectively, driven primarily by robust volume growth across its key products. Net income saw significant increases, up 14% for the quarter and a substantial 84% for the nine-month period, leading to a corresponding surge in diluted Earnings Per Share (EPS). The company demonstrated effective cost management, with operating expenses growing at a slower pace than revenues. Strategic investments in late-stage clinical programs continue, supported by strong operational cash flow generation. The company's balance sheet remains solid, though cash and cash equivalents decreased slightly from year-end 2024, largely due to significant debt repayment and dividend payments. Amgen continues to manage its debt effectively, reducing its overall debt principal. The company also highlighted ongoing legal matters, particularly the significant U.S. Tax Court case, which, while expected to be resolved no earlier than the second half of 2026, continues to be a point of attention. Despite potential regulatory headwinds and ongoing litigation, Amgen's operational performance and strategic investments indicate a positive outlook for future growth.
Financial Highlights
52 data points| Revenue | $9.56B |
| Cost of Revenue | $3.08B |
| Gross Profit | $6.47B |
| SG&A Expenses | $1.72B |
| Operating Expenses | $7.03B |
| Operating Income | $2.53B |
| Interest Expense | $685.00M |
| Net Income | $3.22B |
| EPS (Basic) | $5.98 |
| EPS (Diluted) | $5.93 |
| Shares Outstanding (Basic) | 538.00M |
| Shares Outstanding (Diluted) | 542.00M |
Key Highlights
- 1Total revenues grew by 12% to $9.6 billion for Q3 2025 and 11% to $26.9 billion for the first nine months of 2025.
- 2Net income surged by 14% to $3.2 billion for Q3 2025 and 84% to $6.4 billion for the nine-month period.
- 3Diluted EPS increased by 14% to $5.93 for Q3 2025 and 84% to $11.77 for the nine-month period.
- 4Operating income saw a strong increase of 23% for Q3 2025 to $2.5 billion and 29% for the nine-month period to $6.4 billion.
- 5Product sales showed robust growth, up 12% to $9.1 billion for Q3 and 11% to $25.8 billion for the nine months, driven by volume.
- 6Significant investments in R&D increased by 31% for the quarter and 21% for the nine months, reflecting pipeline advancement.
- 7The company generated $8.4 billion in cash from operating activities for the nine months ended September 30, 2025, a substantial increase from the prior year.